Who is sponsoring NCT04790565?

NCT04790565 is sponsored by Rambam Health Care Campus.

What drugs are being tested in NCT04790565?

Interventions in NCT04790565: FMT.

What condition does NCT04790565 study?

NCT04790565 studies Carbapenem-Resistant Enterobacteriaceae Infection.

Is NCT04790565 still recruiting?

NCT04790565 is currently completed. Last updated 26 October 2022.

Last reviewed 2022-10-26 · How we verify

NCT04790565

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fecal Microbiota Transplantation for Carbapenem Resistant Enterobacteriaceae

Completed Phase 2, PHASE3 Last updated 26 October 2022

What this trial tests

Phase 2, PHASE3 trial testing FMT in Carbapenem-Resistant Enterobacteriaceae Infection in 15 participants. Completed in 1 October 2022.

Timeline

1 April 2021

Primary endpoint
30 June 2022

1 October 2022

Quick facts

Lead sponsor	Rambam Health Care Campus
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 April 2021
Primary completion	30 June 2022
Estimated completion	1 October 2022
Sites	1 location across Israel

Drugs / interventions tested

FMT — full drug profile →

Conditions studied

Carbapenem-Resistant Enterobacteriaceae Infection — all drugs for Carbapenem-Resistant Enterobacteriaceae Infection →

Sponsor

Rambam Health Care Campus — full company profile →

Who can join

Adults 18 to 120, any sex, with Carbapenem-Resistant Enterobacteriaceae Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Open-label, single center, prospective interventional non-comparative study for CRE carriers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Antimicrobial Resistance: The Answers.
Millar BC, Cates MJ, Torrisi MS, Round AJ, et al · · 2026 · PMID 41727556 · DOI 10.3389/bjbs.2026.15559

Verify or expand the search:

Other trials of FMT

Trials testing the same drug.

NCT07386795 — The Efficacy and Safety of Microbiota Transplantation Combined With Prebiotics for Treatment of Functional Constipation · NA · not yet recruiting
NCT07387952 — The Safety and Efficacy of Fecal Microbiota Transplantation Combined With Nutritional Intervention in the Treatment of F · NA · recruiting
NCT07153809 — Fecal Microbiota Transplantation (FMT) in Patients With Moderate to Severe Acute Pancreatitis · NA · recruiting
NCT06496191 — FMT for Alcohol Use Disorder in Cirrhotics. · NA · recruiting
NCT05740319 — Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome · NA · recruiting

Other recruiting trials for Carbapenem-Resistant Enterobacteriaceae Infection

Currently open trials in the same condition.

NCT05979545 — EaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics · Phase 4 · recruiting
NCT06051513 — Efficacy and Safety of Colistimethate Sodium for Injection in The Treatment of Carbapenem-Resistant Enterobacteriaceae I · NA · recruiting
NCT07086391 — Different Methods of Aerosolized Polymyxin B Inhalation for Treating Carbapenem-Resistant Gram-Negative Bacterial Pneumo · recruiting
NCT05871476 — Interventions to Decrease CRE Colonization and Transmission Between Hospitals, Households, Communities and Domesticated · NA · recruiting
NCT04535661 — Risk Factors for Colonization or Infection With Carbapenem-Resistant Enterobacteriaceae in Children · recruiting

Other Rambam Health Care Campus trials

Trials by the same sponsor.

NCT07384013 — Study Protocol: Impact of Metamizole (Optalgin®) on Anti-Xa Concentrations in Oncology Patients Receiving DOACs · NA · recruiting
NCT06688253 — Intravenous Human IgG1 Fc Fragment (Efgartigimod) in Myasthenic Crisis · Phase 4 · not yet recruiting
NCT06235749 — Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery · NA · recruiting
NCT06622902 — Influence of Flow Rate Change on CO2 Levels During High Flow Nasal Ventilation (HFNV) in Preterm Infants. · NA · recruiting
NCT05922111 — Cervical Ripening Balloon for 12 Hours vs. 1 Hour. · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04790565 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rambam Health Care Campus
Last refreshed: 26 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04790565.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing